Answers are grounded in this paper and cite their sources.
Chronic myeloid leukemia (CML) has undergone remarkable therapeutic transformation with the introduction of BCR::ABL1 tyrosine kinase inhibitors (TKIs). However, accumulating evidence indicates that durable disease control depends not only on kinase inhibition, but also on effective anti-leukemic immunity. At diagnosis, both innate and adaptive immunity are profoundly dysregulated, characterized by an impaired natural killer cell function, T-cell exhaustion, the expansion of immunosuppressive cell populations, and the activation of immune checkpoint pathways. TKIs differentially remodel the immune microenvironment through off-target immunomodulatory effects, potentially contributing to treatment-free remission (TFR) in selected patients. Recent studies have further identified leukemic stem cell immune evasion mechanisms, bone marrow niche interactions, and host immunogenetic factors as factors associated with long-term disease control. This review summarizes current advances in cancer immunology in CML and discusses emerging immunological biomarkers and therapeutic strategies to achieve durable immune surveillance, TFR, and a functional cure.
No takes yet. Share an insight, caveat, or question.
Hiroshi Ureshino (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: